← All trials
NCT02652715
N/AInterventional
Trials without FDA-defined phases, including trials of devices or behavioral interventions.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2016
- Primary completion
- May 1, 2021
- Completion date
- May 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Mayo ClinicLead sponsor
- Mayo ClinicOverall official - principal investigator
- National Cancer Institute (NCI)Collaborator
Drugs studied
Indications studied
- Burkitt Lymphoma
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Mycosis Fungoides
- Plasmacytoma
- Sezary Syndrome
- Transplantation
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia-Lymphoma, Adult T-Cell
- Lymphoma, T-Cell
- Lymphoma, Large-Cell, Immunoblastic
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Mantle-Cell
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Lymphoma, Extranodal NK-T-Cell
- Lymphoma, Primary Cutaneous Anaplastic Large Cell
- Lymphoma, Primary Effusion
- Enteropathy-Associated T-Cell Lymphoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.